<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39351097</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Clinical efficacy of Fufang Yinhua Jiedu (FFYH) granules in mild COVID-19 and its anti-SARS-CoV-2 mechanism by blocking autophagy through inhibiting the AKT/mTOR signaling pathway.</ArticleTitle><Pagination><StartPage>1431617</StartPage><MedlinePgn>1431617</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1431617</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1431617</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Fufang Yinhua Jiedu (FFYH) granules are recommended for treating coronavirus pneumonia (COVID-19) in China. However, its anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity and clinical efficacy against COVID-19 remain to be confirmed.</AbstractText><AbstractText Label="AIMS" NlmCategory="UNASSIGNED">Our study aimed to investigate the anti-SARS-CoV-2 effect and potential mechanism of FFYH.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">The activity of FFYH against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was evaluated via cell pathogenic effects, immunoblotting, immunofluorescence staining, and qRT-PCR. The potential mechanism of FFYH against SARS-CoV-2 was investigated by immunoblotting. One head-to-head randomized controlled trial was designed to evaluate the clinical efficacy of FFYH in mild COVID-19. Two hundred patients were randomly recruited to receive either FFYH or LHQW (Lianhua Qingwen) granules.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The <i>in vitro</i> results indicated that FFYH effectively inhibited SARS-CoV-2 replication by suppressing CPE and decreasing viral RNA and protein expression. A time-of-drug-addition assay confirmed that FFYH mainly targeted the binding and replication stages of the SARS-CoV-2 life cycle. Mechanistic studies revealed that blocking SARS-CoV-2-triggered autophagy may be the primary mechanism by which FFYH protects against SARS-CoV-2 infection by regulating the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. Clinical results confirmed that FFYH effectively shortened the recovery time of clinical symptoms and viral nucleic acid negativity, improved abnormal hematology parameters, and controlled excessive cytokine responses in mild COVID-19 patients. Subgroup analysis revealed that FFYH improved the recovery time of clinical symptoms, improved hematological parameters, and controlled excessive cytokine storms to a greater extent in the mild COVID-19 male subgroup, abnormal hematology subgroup, and 32-42-year-old subgroup than in the corresponding LHQW subgroup (<i>P</i> &lt; 0.05). No patients progressed to severe or critical cases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our results indicate that FFYH not only has good anti-viral activity against SARS-CoV-2 but also has significant efficacy against COVID-19, indicating that FFYH may be a novel complementary option for treating COVID-19.</AbstractText><CopyrightInformation>Copyright © 2024 Wang, Zheng, Qi, Wei, Mao, Su, Chen, Feng, Qiao, Ma, Tang, Zhou, Zhuang and Zhang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Wenlei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Medical College, Yangzhou University, Yangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zheng</LastName><ForeName>Zhihui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Medical College, Yangzhou University, Yangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Human Diseases Animal Model Resource Center, NHC Key Laboratory of Human Disease Comparative Medicine, National Center of Technology Innovation for Animal Model, Institute of Laboratory Animal Sciences, Chinese Academy of Medical Science and Peking Union Medical School, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Qi</LastName><ForeName>Xiaoyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Yixing People's Hospital, Yixing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wei</LastName><ForeName>Hailin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Medical College, Yangzhou University, Yangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mao</LastName><ForeName>Xuhua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Yixing People's Hospital, Yixing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Medical College, Yangzhou University, Yangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Yixing People's Hospital, Yixing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yixing People's Hospital, Yixing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Guohong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Yixing People's Hospital, Yixing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Tieliang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Yixing People's Hospital, Yixing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Zhian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Yixing People's Hospital, Yixing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Guangming</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Yixing People's Hospital, Yixing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Jinqiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Emergency Intensive Care Unit (EICU), Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Pinghu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Medical College, Yangzhou University, Yangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Zoonosis, Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Fufang Yinhua Jiedu granules</Keyword><Keyword MajorTopicYN="N">PI3K/AKT/mTOR</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword></KeywordList><CoiStatement>All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39351097</ArticleId><ArticleId IdType="pmc">PMC11439717</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1431617</ArticleId><ArticleId IdType="pii">1431617</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abu-Eid R., Ward F. J. (2021). Targeting the PI3K/Akt/mTOR pathway: a therapeutic strategy in COVID-19 patients. Immunol. Lett. 240, 1–8. 10.1016/j.imlet.2021.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2021.09.005</ArticleId><ArticleId IdType="pmc">PMC8457906</ArticleId><ArticleId IdType="pubmed">34562551</ArticleId></ArticleIdList></Reference><Reference><Citation>Algassim A. A., Elghazaly A. A., Alnahdi A. S., Mohammed-Rahim O. M., Alanazi A. G., Aldhuwayhi N. A., et al. (2021). Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Ann. Hematol. 100, 37–43. 10.1007/s00277-020-04256-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-020-04256-3</ArticleId><ArticleId IdType="pmc">PMC7486165</ArticleId><ArticleId IdType="pubmed">32918594</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliyari S. R., Ghaffari A. A., Pernet O., Parvatiyar K., Wang Y., Gerami H., et al. (2022). Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2. Acta Pharm. Sin. B 12, 1624–1635. 10.1016/j.apsb.2022.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2022.02.019</ArticleId><ArticleId IdType="pmc">PMC8883762</ArticleId><ArticleId IdType="pubmed">35251918</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513. 10.1016/S0140-6736(20)30211-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharra R., Kumar Sharma A., Datta S. (2023). Emerging aspects of cytokine storm in COVID-19: the role of proinflammatory cytokines and therapeutic prospects. Cytokine 169, 156287. 10.1016/j.cyto.2023.156287</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2023.156287</ArticleId><ArticleId IdType="pmc">PMC10291296</ArticleId><ArticleId IdType="pubmed">37402337</ArticleId></ArticleIdList></Reference><Reference><Citation>Djakpo D. K., Wang Z., Zhang R., Chen X., Chen P., Antoine M. (2020). Blood routine test in mild and common 2019 coronavirus (COVID-19) patients. Biosci. Rep. 40. 10.1042/BSR20200817</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20200817</ArticleId><ArticleId IdType="pmc">PMC7414516</ArticleId><ArticleId IdType="pubmed">32725148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes M. B., Barata J. T. (2023). IL-7 and IL-7R in health and disease: an update through COVID times. Adv. Biol. Regul. 87, 100940. 10.1016/j.jbior.2022.100940</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2022.100940</ArticleId><ArticleId IdType="pubmed">36503870</ArticleId></ArticleIdList></Reference><Reference><Citation>Gassen N. C., Papies J., Bajaj T., Emanuel J., Dethloff F., Chua R. L., et al. (2021). SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat. Commun. 12, 3818. 10.1038/s41467-021-24007-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24007-w</ArticleId><ArticleId IdType="pmc">PMC8217552</ArticleId><ArticleId IdType="pubmed">34155207</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506. 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Rubin L., Peng T., Liu L., Xing X., Lazarovici P., et al. (2022). Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int. J. Biol. Sci. 18, 459–472. 10.7150/ijbs.59272</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.59272</ArticleId><ArticleId IdType="pmc">PMC8741849</ArticleId><ArticleId IdType="pubmed">35002503</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R., Sharma B. R., Tuladhar S., Williams E. P., Zalduondo L., Samir P., et al. (2021). Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149–168.e17. 10.1016/j.cell.2020.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.025</ArticleId><ArticleId IdType="pmc">PMC7674074</ArticleId><ArticleId IdType="pubmed">33278357</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. S., Lee J. Y., Yang J. W., Lee K. H., Effenberger M., Szpirt W., et al. (2021). Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 11, 316–329. 10.7150/thno.49713</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.49713</ArticleId><ArticleId IdType="pmc">PMC7681075</ArticleId><ArticleId IdType="pubmed">33391477</ArticleId></ArticleIdList></Reference><Reference><Citation>KräMER B., Knoll R., Bonaguro L., Tovinh M., Raabe J., Astaburuaga-GarcíA R., et al. (2021). Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity 54, 2650–2669.e14. 10.1016/j.immuni.2021.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8416549</ArticleId><ArticleId IdType="pubmed">34592166</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. H., Wang R. Q., Guo W. J., Li J. S. (2016). Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): a meta-analysis. J. Chin. Med. Assoc. 79, 281–291. 10.1016/j.jcma.2015.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcma.2015.10.009</ArticleId><ArticleId IdType="pubmed">26935853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L. L., Shan J. J., Xie T., Xu J. Y., Shen C. S., DI L. Q., et al. (2016). Application of traditional Chinese medical herbs in prevention and treatment of respiratory syncytial virus. Evid. Based Complement. Altern. Med. 2016, 6082729. 10.1155/2016/6082729</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6082729</ArticleId><ArticleId IdType="pmc">PMC5027054</ArticleId><ArticleId IdType="pubmed">27688789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu M., Fan G., Xiao G., Wang T., Xu D., Gao J., et al. (2021). Traditional Chinese medicine in COVID-19. Acta Pharm. Sin. B 11, 3337–3363. 10.1016/j.apsb.2021.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.09.008</ArticleId><ArticleId IdType="pmc">PMC8450055</ArticleId><ArticleId IdType="pubmed">34567957</ArticleId></ArticleIdList></Reference><Reference><Citation>Michot J. M., Albiges L., Chaput N., Saada V., Pommeret F., Griscelli F., et al. (2020). Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann. Oncol. 31, 961–964. 10.1016/j.annonc.2020.03.300</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.03.300</ArticleId><ArticleId IdType="pmc">PMC7136869</ArticleId><ArticleId IdType="pubmed">32247642</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen P., Li J., Tu S., Wu Y., Peng Y., Chen G., et al. (2021). Positive effects of Lianhuaqingwen granules in COVID-19 patients: a retrospective study of 248 cases. J. Ethnopharmacol. 278, 114220. 10.1016/j.jep.2021.114220</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2021.114220</ArticleId><ArticleId IdType="pmc">PMC8139441</ArticleId><ArticleId IdType="pubmed">34029640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Wang H., Liu X., Xu D., Tang Y., Luo P. (2014). Traditional Chinese medicine for the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials. J. Tradit. Chin. Med. 34, 527–531. 10.1016/s0254-6272(15)30057-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0254-6272(15)30057-1</ArticleId><ArticleId IdType="pubmed">25417400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei H., Wang W., Su Q., Zheng Z., Chen Z., Zhang X., et al. (2024). Network pharmacology-based study to investigate the mechanism of compound houttuynia mixture against influenza virus infection by suppressing TLR7/MyD88 signaling pathway. J. Traditional Complementary Med. 10.1016/j.jtcme.2024.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcme.2024.03.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing D., Liu Z. (2021). Effectiveness and safety of traditional Chinese medicine in treating COVID-19: clinical evidence from China. Aging Dis. 12, 1850–1856. 10.14336/AD.2021.0906</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2021.0906</ArticleId><ArticleId IdType="pmc">PMC8612612</ArticleId><ArticleId IdType="pubmed">34881072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Xie X., Tu Z., Fu J., Xu D., Zhou Y. (2021). The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target Ther. 6, 255. 10.1038/s41392-021-00679-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00679-0</ArticleId><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Shen C., Li J., Yuan J., Wei J., Huang F., et al. (2020). Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J. Allergy Clin. Immunol. 146, 119–127. 10.1016/j.jaci.2020.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.04.027</ArticleId><ArticleId IdType="pmc">PMC7189843</ArticleId><ArticleId IdType="pubmed">32360286</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J. S., Ho C. H., Hsu Y. C., Wang J. J., Hsieh C. L. (2014). Traditional Chinese medicine treatments for upper respiratory tract infections/common colds in Taiwan. Eur. J. Integr. Med. 6, 538–544. 10.1016/j.eujim.2014.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eujim.2014.06.003</ArticleId><ArticleId IdType="pmc">PMC7102745</ArticleId><ArticleId IdType="pubmed">32288884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M. M., Liu X. M., He L. (2004). Effect of integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence. World J. Gastroenterol. 10, 3500–3505. 10.3748/wjg.v10.i23.3500</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v10.i23.3500</ArticleId><ArticleId IdType="pmc">PMC4576235</ArticleId><ArticleId IdType="pubmed">15526373</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Zhang B., Lv J. T., Sa R. N., Zhang X. M., Lin Z. J. (2020a). The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence. Pharmacol. Res. 157, 104882. 10.1016/j.phrs.2020.104882</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104882</ArticleId><ArticleId IdType="pmc">PMC7198419</ArticleId><ArticleId IdType="pubmed">32380051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wu L., Xu X., Yuan Y., Jiang R., Yan X., et al. (2022a). Effectiveness of lianhua qingwen capsule in treatment of asymptomatic COVID-19 patients: a randomized, controlled multicenter trial. J. Integr. Complement. Med. 28, 887–894. 10.1089/jicm.2021.0352</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jicm.2021.0352</ArticleId><ArticleId IdType="pubmed">36342811</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Zhang Z., Ye Y., Luo Y., Pan S., Qi H., et al. (2020b). Lymphocyte percentage and hemoglobin as a joint parameter for the prediction of severe and nonsevere COVID-19: a preliminary study. Ann. Transl. Med. 8, 1231. 10.21037/atm-20-6001</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-6001</ArticleId><ArticleId IdType="pmc">PMC7607120</ArticleId><ArticleId IdType="pubmed">33178763</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Yuan H., Yang Z., Hu X., Mahmmod Y. S., Zhu X., et al. (2022b). SARS-CoV-2: an updated review highlighting its evolution and treatments. Vaccines (Basel) 10, 2145. 10.3390/vaccines10122145</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122145</ArticleId><ArticleId IdType="pmc">PMC9780920</ArticleId><ArticleId IdType="pubmed">36560555</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Wang R., Shi W., Zheng Z., Wang X., Li C., et al. (2021). Antiviral effect of fufang yinhua jiedu (FFYH) granules against influenza A virus through regulating the inflammatory responses by TLR7/MyD88 signaling pathway. J. Ethnopharmacol. 275, 114063. 10.1016/j.jep.2021.114063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2021.114063</ArticleId><ArticleId IdType="pmc">PMC9759603</ArticleId><ArticleId IdType="pubmed">33813013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z., Wang K., Wei H., Wang W., We J., Wangi R., et al. (2022). Antiviral effect of fufang yinhua jiedu (FFYH) granules against coronavirus and its potential mechanism. Acta Pharmaceutica Sinica. 57, 1808–1815. 10.16438/j.0513-4870.2021-1815</Citation><ArticleIdList><ArticleId IdType="doi">10.16438/j.0513-4870.2021-1815</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Chen D., Zhu Y., Ge X., Li Z., Miao H. (2023). Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia. J. Int. Med. Res. 51, 3000605221149292. 10.1177/03000605221149292</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605221149292</ArticleId><ArticleId IdType="pmc">PMC9972059</ArticleId><ArticleId IdType="pubmed">36843426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zizzo G., Tamburello A., Castelnovo L., Laria A., Mumoli N., Faggioli P. M., et al. (2022). Immunotherapy of COVID-19: inside and beyond IL-6 signalling. Front. Immunol. 13, 795315. 10.3389/fimmu.2022.795315</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.795315</ArticleId><ArticleId IdType="pmc">PMC8948465</ArticleId><ArticleId IdType="pubmed">35340805</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>